| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J9225 | Histrelin Acetate | Vantas | 50 mg | Hormonal Therapy | GnRH Agonist | No | 2004 | Jan 1, 2008 | In Use | |||
| NA | Vorinostat | Erivedge | 100 mg | Chemotherapy | Enzyme Inhibitor | HDAC | Yes | 2006 | In Use | |||
| J8650 | Nabilone | Cesamet | 1 mg | Ancillary Therapy | Antiemetic | Cannabinoid | Yes | 1985 | Jan 1, 2007 | In Use | ||
| N/A | Vepdegestrant | Veppanu | 100mg, 200mg | Hormonal Therapy | Proteolysis Targeting Chimera (PROTAC) | ER, Cereblon/CRBN | Yes | 2026 | In Use | |||
| J9276 | Zanidatamab-hrii | ZIIHERA | 2mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2024 | Jul 9, 2025 | In Use | ||
| N/A | Zidesamtinib | Jideytro | 25mg, 100mg | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, ALK, TRK | Yes | 2026 | In Use | |||
| NA | idelalisib | Zydelig | 100 mg | Chemotherapy | Enzyme Inhibitor | PI3K | Yes | 2014 | In Use | |||
| NA | lenvatinib | Lenvima | 10 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR,KIT,RET | Yes | 2015 | In Use | |||
| NA | Thalidomide | Thalomid | 50 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 1998 | In Use | |||
| J9226 | Histrelin Acetate | Supprelin LA | 50 mg | Hormonal Therapy | GnRH Agonist | No | 2004 | Jan 1, 2008 | In Use | |||
| C9175 | Treosulfan | Grafapex | 50mg | Chemotherapy | Alkylating Agent | Alkyl Sulfonate | No | 2025 | Jul 9, 2025 | Sep 8, 2025 | In Use | |
| NA | Trifluridine and Tipiracil | Lonsurf | 15/6.14 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | Yes | 2015 | In Use | |||
| NA | sonidegib | odozmo | 200 mg | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Yes | 2015 | In Use | |||
| NA | venetoclax | Venclexta | 10 mg | Chemotherapy | Enzyme Inhibitor | BCL-2 | Yes | 2016 | In Use | |||
| NA | venetoclax | Venclexta | 50 mg | Chemotherapy | Enzyme Inhibitor | BCL-2 | Yes | 2016 | In Use | |||
| NA | Binimetinib | Mektovi | 15mg | Chemotherapy | MEK Inhibitor | MEK 1/2 | Yes | 2018 | In Use | |||
| J9055 | Cetuximab | Erbitux | 10 mg | Immunotherapy | Monoclonal Antibody | EGFR | No | 2004 | Jan 1, 2005 | In Use | ||
| Q2055 | Idecabtagene vicleucel | Abecma | 460 million | Immunotherapy | CAR-T | BCMA | No | 2021 | Jan 26, 2022 | In Use | ||
| NA | Erlotinib | Tarceva | 150 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2004 | In Use | |||
| J8999 | Chemotherapy - non specific | Prescription drug, oral, chemotherapeutic NOS | NA | Chemotherapy | Yes | In Use | ||||||
| S0172 | Chlorambucil | Leukeran | 2 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Yes | 1957 | Jan 1, 2002 | In Use | ||
| NA | Selpercatinib | Retevmo | 40mg, 80mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2020 | In Use | |||
| N/A | Imlunestrant | Inluriyo | 200mg | Hormonal Therapy | Estrogen Receptor Antagonist | ER⍺ | Yes | 2025 | In Use | |||
| C9145 | Aprepitant | Aponvie | 1mg | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | No | 2023 | Mar 17, 2023 | Mar 18, 2026 | In Use | |
| J9361 | Efbemalenograstim alfa-vuxw | Ryzneuta | 0.5mg | Immunotherapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | No | 2023 | Jun 10, 2024 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home